(2R,3S,5R)-5-(2,4-dioxo-5-(trifluoromethyl)-3,4-dihydropyrimidin-1(2H)-yl)-2-(((4-methylbenzoyl)oxy)methyl)tetrahydrofuran-3-yl-4-methylbenzoate | 7057-46-7

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: (2R,3S,5R)-5-(2,4-dioxo-5-(trifluoromethyl)-3,4-dihydropyrimidin-1(2H)-yl)-2-(((4-methylbenzoyl)oxy)methyl)tetrahydrofuran-3-yl-4-methylbenzoate
• 英文别名: thymidine,α,α,α-trifluoro-,3',5'-bis(4-methylbenzoate)；Thymidine, alpha,alpha,alpha-trifluoro-, 3',5'-bis(4-methylbenzoate)；[(2R,3S,5R)-5-[2,4-dioxo-5-(trifluoromethyl)pyrimidin-1-yl]-3-(4-methylbenzoyl)oxyoxolan-2-yl]methyl 4-methylbenzoate
• CAS: 7057-46-7
• 化学式: C₂₆H₂₃F₃N₂O₇
• 分子量: 532.473
• InChiKey: QFTZSUBIJAWRPF-PWRODBHTSA-N

物化性质

• 密度：
  1.44±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  38
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  111
• 氢给体数：
  1
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  (2R,3S,5R)-5-(2,4-dioxo-5-(trifluoromethyl)-3,4-dihydropyrimidin-1(2H)-yl)-2-(((4-methylbenzoyl)oxy)methyl)tetrahydrofuran-3-yl-4-methylbenzoate 在 甲醇 、 sodium methylate 作用下， 反应 1.5h， 以39 g的产率得到三氟胸苷
  参考文献：
  名称：

  [EN] SOLID STATE FORMS OF 5-CHLORO-6-[(2-IMINOPYRROLIDIN-1-YL)METHYL]PYRIMIDINE-2,4-(1H,3H)-DIONE HYDROCHLORIDE AND THEIR PROCESSES FOR THE PREPARATION THEREOF
  [FR] FORMES À L'ÉTAT SOLIDE DE CHLORHYDRATE DE 5-CHLORO-6-[(2-IMINOPYRROLIDIN-1-YL)MÉTHYL]PYRIMIDINE-2,4-(1H,3H)-DIONE ET PROCÉDÉS DE PRÉPARATION ASSOCIÉS

  摘要：

  本发明涉及化合物5-氯-6-[(2-亚胺吡咯啉-1-基)甲基]嘧啶-2,4-(1H,3H)-二酮盐酸盐的固态形式，其化学式为1a，以及其制备方法和改进的制备方法。本发明者还提供了由2'-脱氧-5-(三氟甲基)尿苷和5-氯-6-[(2-亚胺吡咯啉-1-基)甲基]嘧啶-2,4-(1H,3H)-二酮单盐酸组成的组合药物的非晶形态多晶形态及其制备方法。

  公开号：

  WO2019049174A1
• 作为产物：
  描述：

  甲基-2-脱氧-D-核糖 在 盐酸 、 4-二甲氨基吡啶 、 三甲基氯硅烷 、 溶剂黄146 、 三乙胺 、 乙酰氯 、 六甲基二硅氮烷 作用下， 以 1,4-二氧六环 、 氯仿 、 甲苯 为溶剂， 反应 11.25h， 生成 (2R,3S,5R)-5-(2,4-dioxo-5-(trifluoromethyl)-3,4-dihydropyrimidin-1(2H)-yl)-2-(((4-methylbenzoyl)oxy)methyl)tetrahydrofuran-3-yl-4-methylbenzoate
  参考文献：
  名称：

  [EN] SOLID STATE FORMS OF 5-CHLORO-6-[(2-IMINOPYRROLIDIN-1-YL)METHYL]PYRIMIDINE-2,4-(1H,3H)-DIONE HYDROCHLORIDE AND THEIR PROCESSES FOR THE PREPARATION THEREOF
  [FR] FORMES À L'ÉTAT SOLIDE DE CHLORHYDRATE DE 5-CHLORO-6-[(2-IMINOPYRROLIDIN-1-YL)MÉTHYL]PYRIMIDINE-2,4-(1H,3H)-DIONE ET PROCÉDÉS DE PRÉPARATION ASSOCIÉS

  摘要：

  本发明涉及化合物5-氯-6-[(2-亚胺吡咯啉-1-基)甲基]嘧啶-2,4-(1H,3H)-二酮盐酸盐的固态形式，其化学式为1a，以及其制备方法和改进的制备方法。本发明者还提供了由2'-脱氧-5-(三氟甲基)尿苷和5-氯-6-[(2-亚胺吡咯啉-1-基)甲基]嘧啶-2,4-(1H,3H)-二酮单盐酸组成的组合药物的非晶形态多晶形态及其制备方法。

  公开号：

  WO2019049174A1

文献信息

• Studies on antitumor agents. VI. Syntheses and antitumor activities of acyl derivatives of 2'-deoxy-5-trifluoromethyluridine.
  作者：JUN-ICHI YAMASHITA、SETSUO TAKEDA、HIROSHI MATSUMOTO、TADAFUMI TERADA、NORIO UNEMI、MITSUGI YASUMOTO

  DOI：10.1248/cpb.35.2090

  日期：——

  Various O-acyl and N-acyl derivatives of 2'-deoxy-5-trifluoromethyluridine (F3Thd) were synthesized; namely 5'-O-acyl, 3', 5'-di-O-acyl, N3-acyl, 3', 5'-di-O-acetyl-N3-acyl, 3', 5'-di-O-carbamoyl and 3', 5'-di-O-ethoxycarbonyl compounds. 5'-O-Acyl derivatives of 2'-deoxy-5-trifluoromethylcytidine were also synthesized. The antitumor activities of these compounds against sarcoma 180 were examined by oral administration to mice. Among the 5'-and 3', 5'-diester compounds with aliphatic acids, the 5'-O-hexanoyl compound showed the highest activity. Full protection of the sugar moiety with aroyl or carbamoyl groups considerably decreased the activities, and those of the 3', 5'-di-O-m-fluorobenzoyl and 3, 5'-di-O-butylcarbamoyl compounds were the smallest. N3-Benzoyl compounds were slightly more effective than F3Thd but none of them showed higher activity than the effective O-acyl compounds. In the case of 5'-O-acylates of 2'-deoxy-5-trifluoromethylcytidine, the 5'-O-benzoyl compound showed the highest activity.

  合成了2'-脱氧-5-三氟甲基尿苷(F3Thd)的各种O-酰基和N-酰基衍生物,即5'-O-酰基、3', 5'-二-O-酰基、N3-酰基、3',5'-二-O-乙酰基-N3-酰基、3', 5'-二-O-氨甲酰基和3',5'-二-O-乙氧羰基化合物。还合成了2'-脱氧-5-三氟甲基胞苷的5'-O-酰基衍生物。通过给小鼠口服给药,考察了这些化合物对肉瘤180的抗癌活性。在具有脂肪族酸的5'-和3'5'-二酯化合物中,5'-O-己酰基化合物显示出最高的活性。用芳酰基或氨甲酰基保护糖部分的完全保护大大降低了活性,而3',5'-二-O-间氟苯甲酰基和3',5'-二-O-丁基氨甲酰基化合物的活性最小。N3-苯甲酰基化合物的效力略高于F3Thd,但它们中没有任何一种显示出比有效的O-酰基化合物更高的活性。在2'-脱氧-5-三氟甲基胞苷的5'-O-酰基化合物中,5'-O-苯甲酰基化合物显示出最高的活性。
• [EN] SOLID STATE FORMS OF 5-CHLORO-6-[(2-IMINOPYRROLIDIN-1-YL)METHYL]PYRIMIDINE-2,4-(1H,3H)-DIONE HYDROCHLORIDE AND THEIR PROCESSES FOR THE PREPARATION THEREOF<br/>[FR] FORMES À L'ÉTAT SOLIDE DE CHLORHYDRATE DE 5-CHLORO-6-[(2-IMINOPYRROLIDIN-1-YL)MÉTHYL]PYRIMIDINE-2,4-(1H,3H)-DIONE ET PROCÉDÉS DE PRÉPARATION ASSOCIÉS
  申请人：MSN LABORATORIES PRIVATE LTD R&D CENTER

  公开号：WO2019049174A1

  公开（公告）日：2019-03-14

  The present invention relates to solid state forms of 5-chloro-6-[(2-iminopyrrolidin-1-yl)methyl]pyrimidine-2,4-(1H,3H)-dione hydrochloride compound of formula-1a and their processes for the preparation thereof and an improved process for the preparation of 5-chloro-6-[(2-iminopyrrolidin-1-yl)methyl]pyrimidine-2,4-(1H,3H)-dione hydrochloride. The present inventors also provides an amorphous polymorph of the combination drug consisting of 2'-deoxy-5-(trifluoromethyl) uridine and 5-chloro-6-[(2-iminopyrrolidin-1-yl)methyl]pyrimidine-2,4-(1H,3H)-dione monohydrochloride and its process for the preparation.

  本发明涉及化合物5-氯-6-[(2-亚胺吡咯啉-1-基)甲基]嘧啶-2,4-(1H,3H)-二酮盐酸盐的固态形式，其化学式为1a，以及其制备方法和改进的制备方法。本发明者还提供了由2'-脱氧-5-(三氟甲基)尿苷和5-氯-6-[(2-亚胺吡咯啉-1-基)甲基]嘧啶-2,4-(1H,3H)-二酮单盐酸组成的组合药物的非晶形态多晶形态及其制备方法。